EU investors sound the alarm

A confluence of falling equity and R&D investment in Europe, coupled with geopolitical instability, has convinced a group of blue-chip European VCs that now is the moment to mount a coordinated push to strengthen domestic biotech financing — and to press for policy and regulatory changes aimed at improving Europe’s competitiveness with the U.S. and China.

“We need to begin these conversations,” Omega Funds’ Otello Stampacchia told BioCentury. “Otherwise there’s a real danger that not too many years from now, the entire infrastructure will fall apart and this ecosystem won’t be here anymore,” ...